Compare XYF & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | XYF | RZLT |
|---|---|---|
| Founded | 2014 | 2010 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 260.6M | 1.0B |
| IPO Year | 2018 | N/A |
| Metric | XYF | RZLT |
|---|---|---|
| Price | $6.63 | $2.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $12.33 |
| AVG Volume (30 Days) | 243.8K | ★ 9.8M |
| Earning Date | 11-20-2025 | 11-06-2025 |
| Dividend Yield | ★ 7.87% | N/A |
| EPS Growth | ★ 49.84 | N/A |
| EPS | ★ 5.72 | N/A |
| Revenue | ★ $1,106,908,607.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.24 | ★ N/A |
| Revenue Growth | ★ 47.14 | N/A |
| 52 Week Low | $6.47 | $1.07 |
| 52 Week High | $20.36 | $11.46 |
| Indicator | XYF | RZLT |
|---|---|---|
| Relative Strength Index (RSI) | 26.86 | 25.51 |
| Support Level | $6.68 | $1.07 |
| Resistance Level | $7.28 | $1.85 |
| Average True Range (ATR) | 0.39 | 0.64 |
| MACD | 0.15 | -0.98 |
| Stochastic Oscillator | 15.04 | 10.00 |
X Financial is a Cayman Islands-based technology-driven personal finance company. Along with its subsidiaries, the firm provides diversified investment opportunities to investors in China through its wealth management platform, Xiaoying Wealth Management. Loan products offered by the company include Xiaoying Card Loan, Xiaoying Preferred Loan, and Xiaoying Housing Loan. The company generates revenue from loan facilitation service, post-origination service, and guarantee services provided.
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.